Sirtris Pharmaceuticals, Inc.

Science Links

2007-07-24T04:02:00.001-07:00

Science Links

Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006 Nov 16;444(7117):337-42.
Read more...

Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1alpha. Cell. 2006 Nov 15 Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J.Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1alpha. Cell. 2006 Nov 15
Read more...

Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005 Mar 3;434(7029):113-8.
Read more...

Porcu M, Chiarugi A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci. 2005 Feb;26(2):94-103.
Read more...

Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 2004 Aug 13;305(5686):1010-3.
Read more...

Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans.
Nature. 2004 Aug 5;430(7000):686-9.
Read more...

Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004 Jul 16;305(5682):390-2.
Read more...

Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003 Sep 11;425(6954):191-6.
Read more...

Latest links

2007-07-24T03:59:00.000-07:00

Jun 23, 06
	NEW STORY
08:30 ET	Sirtris Pharmaceuticals to Present at Euro-Biotech Forum, June 29th, 2006
Jun 22, 06
	NEW STORY
08:35 ET	Sirtris Pharmaceuticals to Present at Jefferies Life Science Conference, June 28th 2006
Jun 16, 06
13:35 ET	Sirtris Pharmaceuticals CEO Christoph Westphal Wins Ernst & Young New England Entrepreneur of the Year Award
Jun 07, 06
08:00 ET	Sirtris Announces First Phase 1 Trial of a Sirtuin Therapeutic
Apr 21, 06
08:50 ET	The ALS Association Awards Research Funding for a Novel Compound Developed by Sirtris Pharmaceuticals
Apr 20, 06
08:30 ET	Sirtris Pharmaceuticals Secures $37 Million in Financing
Mar 28, 06
08:00 ET	Sirtris Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference 2006
Mar 01, 06
08:33 ET	Sirtris Pharmaceuticals to Present at SG Cowen 26th Annual Health Care Conference
Feb 13, 06
08:34 ET	Sirtris Pharmaceuticals' Science of Sirtuins Highlighted by Scientific American Cover Article on Scientific Discoveries and Therapeutic Potential of Sirtuins to Treat Age-Related Diseases
Feb 08, 06
08:32 ET	Sirtris Pharmaceuticals to Present at BIO CEO & Investor Conference 2006
Feb 01, 06
08:31 ET	Sirtris Pharmaceuticals Hires Garen Bohlin as Chief Operating Officer
Jan 03, 06
09:30 ET	Sirtris Pharmaceuticals to Present at JP Morgan 24th Annual Healthcare Conference
Nov 30, 05
08:31 ET	Sirtris Pharmaceuticals Hires Peter Elliott as SVP, Head of Development
May 19, 05
11:00 ET	Sirtris Pharmaceuticals, Targeting Class III Histone Deacetylases (HDACs), Completes Exclusive License to Washington University School of Medicine in St. Louis' Intellectual Property

Clinical Trials

2007-07-18T02:02:00.000-07:00

Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that it presented data from pre-clinical and Phase 1a studies at the 6th Annual Metabolic Diseases Drug Discovery and Development World Summit in San Diego, California on July 17, 2007. As previously announced, Jill Milne, Ph.D., Senior Director of Biology at Sirtris, delivered a keynote address "SIRT1 Activation: A Novel Mechanism for Treating Type 2 Diabetes."
Dr. Milne presented data which showed that SRT501, Sirtris' proprietary formulation of resveratrol, reduces glucose and improves insulin sensitivity in multiple pre-clinical models of Type 2 Diabetes. Dr. Milne also presented pharmacokinetic (PK) data from a Phase 1a study conducted by Sirtris in which healthy volunteers who were dosed with SRT501 had an improved exposure as compared with other published studies. Both the area under the curve concentrations (AUC) as well as the maximal concentrations (Cmax) were shown to be improved with SRT501 as compared with literature values for resveratrol. SRT501 is currently being tested in a Phase 1b study in patients with Type 2 Diabetes.

2007-07-18T02:01:00.000-07:00

July 17, 2007 12:00 PM Eastern Daylight Time
Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007
Metabolic Diseases Drug Discovery and Development World Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that it presented data from pre-clinical and Phase 1a studies at the 6th Annual Metabolic Diseases Drug Discovery and Development World Summit in San Diego, California on July 17, 2007. As previously announced, Jill Milne, Ph.D., Senior Director of Biology at Sirtris, delivered a keynote address “SIRT1 Activation: A Novel Mechanism for Treating Type 2 Diabetes.”

Dr. Milne presented data which showed that SRT501, Sirtris' proprietary formulation of resveratrol, reduces glucose and improves insulin sensitivity in multiple pre-clinical models of Type 2 Diabetes. Dr. Milne also presented pharmacokinetic (PK) data from a Phase 1a study conducted by Sirtris in which healthy volunteers who were dosed with SRT501 had an improved exposure as compared with other published studies. Both the area under the curve concentrations (AUC) as well as the maximal concentrations (Cmax) were shown to be improved with SRT501 as compared with literature values for resveratrol. SRT501 is currently being tested in a Phase 1b study in patients with Type 2 Diabetes.

Furthermore, Dr. Milne presented data with certain Sirtris proprietary novel chemical SIRT1 activators, structurally unrelated to resveratrol, which were shown to reduce glucose, improve insulin sensitivity, improve glucose tolerance, and increase the number and function of mitochondria in multiple pre-clinical models of Type 2 Diabetes. In addition, studies in a pre-clinical model demonstrate improved insulin sensitivity in muscle, liver, and fat cells.

“Sirtris scientists continue to make significant progress in the development of SIRT1 activators for diseases of aging such as Type 2 Diabetes. Indeed, the new data presented today further extend Sirtris’ scientific leadership in advancing sirtuin modulators as a new class of innovative therapeutics,” said Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris.

About Sirtris Pharmaceuticals

Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, the progress of pre-clinical and clinical studies of SIRT1 activators, the results of pre-clinical studies as compared with other published studies, Sirtris’ position in the sirtuin field, and the potential for sirtuin modulators to receive regulatory approval. These forward-looking statements about future expectations, plans and prospects of Sirtris Pharmaceuticals involve significant risks, uncertainties and assumptions, including risks related to the lack of results that would provide a basis for predicting whether any of the Company’s product candidates will be safe or effective, or receive regulatory approval, the possibility that results of pre-clinical studies are not necessarily predictive of clinical trial results, the Company's potential inability to initiate and complete pre-clinical studies and clinical trials for its product candidates, the fact that none of the Company's product candidates has received regulatory approvals, the potential inability of the Company to gain market acceptance of the Company's product candidates, and those other risks factors that can be found in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those Sirtris Pharmaceuticals contemplated by these forward-looking statements. Sirtris Pharmaceuticals does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

Contacts
Investor Contact:
Sirtris Pharmaceuticals, Inc.
Michelle Dipp, M.D., Ph.D., 617-252-6920
or
Media Contact:
Pure Communications
Sheryl Seapy, 949-608-0841